• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Intercure Ltd.

    5/16/22 1:02:53 PM ET
    $INCR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $INCR alert in real time by email
    SC 13G 1 ea160053-13getf_intercure.htm SCHEDULE 13G

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. __)*

     

    Intercure Ltd.
    (Name of Issuer)
     
    Common Stock, $0.001 Par Value Per Share
    (Title of Class of Securities)
     
    M549GJ111
    (CUSIP Number)
     
    May 13, 2022
    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☒Rule 13d-1(b)

     

    ☐Rule 13d-1(c)

     

    ☐Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    SCHEDULE 13G

     

    CUSIP No.

    M549GJ111

     

     

    1 Names of Reporting Persons
    ETF Managers Group LLC
    2 Check the appropriate box if a member of a Group (see instructions)
    (a)  ☐
    (b)  ☒ See Item of attached schedule
    3 Sec Use Only
    4 Citizenship or Place of Organization
    Delaware

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With:

     

    5 Sole Voting Power
    2,599,590
    6 Shared Voting Power
     
    7 Sole Dispositive Power
    2,599,590
    8 Shared Dispositive Power
     
    9 Aggregate Amount Beneficially Owned by Each Reporting Person
    2,599,590
    10 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
    ☐
    11 Percent of class represented by amount in row (9)
    5.76%
    12 Type of Reporting Person (See Instructions)
    IA

     

    Page 2 of 5

     

     

    Item 1.

     

    (a)Name of Issuer: Intercure Ltd.

     

    (b)Address of Issuer’s Principal Executive Offices: The Jewish State, Herzliya 4676-670, IL

     

    (a)Name of Person Filing: ETF Managers Group LLC

     

    (b)Address of Principal Business Office or, if None, Residence:

     

    ETF Managers Group LLC - 30 Maple Street, Suite 2, Summit, New Jersey 07091

     

    (c)Citizenship: ETF Managers Group LLC – Delaware

     

    (d)Title and Class of Securities: Common Stock

     

    (e)CUSIP No.:  M549GJ111

     

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)☐ Broker or dealer registered under Section 15 of the Act;

     

    (b)☐ Bank as defined in Section 3(a)(6) of the Act;

     

    (c)☐ Insurance company as defined in Section 3(a)(19) of the Act;

     

    (d)☐ Investment company registered under Section 8 of the Investment Company Act of 1940;

     

    (e)☒ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);

     

    (f)☐ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

     

    (g)☐ A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

     

    (h)☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

    (i)☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;

     

    (j)☐ A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);

     

    (k)☐ Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

     

    Page 3 of 5

     

     

    Item 4.Ownership

     

    (a)Amount Beneficially Owned:   2,599,590

     

    (b)Percent of Class: 5.76%

     

    (c)Number of shares as to which such person(s) has:

     

    (i)Sole power to vote or to direct the vote:  2,599,590

     

    (ii)Shared power to vote or to direct the vote:

     

    (iii)Sole power to dispose or to direct the disposition of:   2,599,590

     

    (iv)Shared power to dispose or to direct the disposition of:

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

     

    Item 6.Ownership of more than Five Percent on Behalf of Another Person.

     

    The ETFMG Alternative Harvest ETF, a series of the ETF Managers Trust, which is managed on a discretionary basis by ETF Managers Group LLC, has the right or the power to direct the receipt of dividends, or the proceeds from the sale of, the Common Stock.

     

    Item 7.Identification and classification of the subsidiary which acquired the security being reported on by the parent holding company or control person.

     

    Not Applicable

     

    Item 8.Identification and classification of members of the group.

     

    Not Applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not Applicable

     

    Item 10.Certifications.

     

    By signing below, we certify that, to the best of our knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    Page 4 of 5

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of our knowledge and belief, we certify that the information set forth in this statement is true, complete and correct.

     

    Dated:  May 16, 2022

     

    /s/ Reshma A. Tanczos  

     

    Name/Title:  Reshma A. Tanczos, Chief Compliance Officer, ETF Managers Group LLC

     

    Page 5 of 5

     

    Get the next $INCR alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $INCR

    DatePrice TargetRatingAnalyst
    5/18/2022$13.00Speculative Buy → Buy
    Canaccord Genuity
    More analyst ratings

    $INCR
    SEC Filings

    See more
    • SEC Form 6-K filed by Intercure Ltd.

      6-K - Intercure Ltd. (0001857030) (Filer)

      5/1/25 4:10:06 PM ET
      $INCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 20-F filed by Intercure Ltd.

      20-F - Intercure Ltd. (0001857030) (Filer)

      4/30/25 9:42:57 PM ET
      $INCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form NT 20-F filed by Intercure Ltd.

      NT 20-F - Intercure Ltd. (0001857030) (Filer)

      4/30/25 8:14:01 PM ET
      $INCR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INCR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • InterCure Announces FY2024 Results and Provides Q1 2025 Update: Revenue of NIS 239 Million and Adjusted EBITDA of NIS 24 Million, Strong Start to 2025

      2024 results were affected by damages to our southern facility caused by the terrorist attack on October 7, 2023, and the continued war in Gaza. InterCure is entitled to full compensation from the Israeli authorities for all direct and indirect damages caused to the southern facility. InterCure received NIS 62 million until December 31, 2024 (to date, NIS 82 million) as partial advanced payments from the Israeli authorities and expects to receive additional substantial payments.Revenues in 2024 reached NIS 239 million, alongside an Adjusted EBITDA[1] of NIS 24 million (approximately 10% of revenues).InterCure announced expansion of its strategic partnership with Cookies™ to Germany and expec

      5/1/25 4:00:00 PM ET
      $INCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • InterCure Names Alexander Rabinovich as Chairman Replacing Ehud Barak

      NEW YORK and HERZLIYA, Israel, Feb. 12, 2025 /PRNewswire/ -- InterCure Ltd. (NASDAQ:INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), announces today that Mr. Ehud Barak will step down as Chairman of the board of directors of the Company (the "Board"), effective February 13, 2025. He will be succeeded by Mr. Alexander Rabinovich, who has successfully led the Company as CEO for the past five years, executing hundreds of percentages of profitable growth, building strategic international partnerships, and establishing InterCure's position as a leader in pharmaceutical cannabis. Mr. Barak, who is marking his 83rd birthday today, has decided to pursue personal endeavors after six

      2/12/25 6:35:00 PM ET
      $INCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • InterCure has Secured Funding of NIS 66M to support the recovery of Nir Oz Facility

      The funding may increase to NIS 107M to support the expansion of the facility in collaboration with the "Tkumah" administration, post-war.The funding includes investments from key shareholders of the company, including CEO Alexander Rabinovich, as well as lead investors Yaron Yakobi and Tzahi Hagag who will become significant shareholders. Funding also includes a loan from a major Israeli bank.Completing the post-war damage recovery processes will enable the company to return to profitable growth without further delay, including exercising the cookies agreement and expanding international operations in Germany, the UK, and Australia.The Company anticipates receiving additional substantial p

      12/20/24 8:32:00 AM ET
      $INCR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INCR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • InterCure upgraded by Canaccord Genuity with a new price target

      Canaccord Genuity upgraded InterCure from Speculative Buy to Buy and set a new price target of $13.00

      5/18/22 7:21:05 AM ET
      $INCR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INCR
    Financials

    Live finance-specific insights

    See more
    • InterCure Reschedules 2022 Full Year Results Conference Call

      NEW YORK, TORONTO, and HERZLIYA, Israel, April 03, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TSX:INCR) (TASE: INCR) (dba Canndoc)("InterCure" or the "Company") announced today that it has rescheduled its previously announced conference call to discuss the company's financial results for the full year ended December 31, 2022. The call was originally scheduled for April 3 at 4:30 P.M. (Eastren time) but has been rescheduled to April 4, at 4:30 P.M. (Eastren time) due to unforeseen circumstances which caused technical issues. Participants can access the live webcast and conference call through the following link: https://register.vevent.com/register/BIdec7603751894ebcbf0f22eca9

      4/3/23 3:27:01 PM ET
      $INCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • InterCure Announces Record Fourth Quarter and Fiscal Year End 2022 Results

      Record fiscal year 2022 revenue of $150 million Record fiscal year 2022 Adjusted EBITDA* of $32 million Record fiscal year 2022 net income of $17 million Generated $20 Million cash flow from operations Strong balance sheet with over $95 million cash NEW YORK, TORONTO, and HERZLIYA, Israel, March 31, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TSX:INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company") is pleased to announce its financial and operating results for the fourth quarter and year ended December 31, 2022. All amounts are expressed in New Israeli Shekels (NIS) or Canadian dollars ($), unless otherwise noted. Full Year 2022 Key Financial & Operating High

      3/31/23 8:00:49 PM ET
      $INCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • InterCure Reports Record Breaking Second Quarter Financial Results

      Record revenue of over $37 millioni in the second quarter of 2022 Representing an annual run rate of $150 million Adjusted EBITDAii for Q2 increased 90% YoY to $9 million Net income of $6 million for the Q2 of 2022 compared to $2 million in Q2 of 2021 Tenth consecutive quarter of profitable growth Eighth consecutive quarter of positive cash flow from operations $96 million cash on hand Revenue growth expected to continue in the third quarter and throughout 2022 NEW YORK and TORONTO and HERZLIYA, Israel, Aug. 15, 2022 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TSX:INCR) (TASE: INCR) ("InterCure" or the "Company") is pleased to announce its financial results

      8/15/22 9:15:00 AM ET
      $INCR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INCR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Intercure Ltd.

      SC 13G - Intercure Ltd. (0001857030) (Subject)

      5/16/22 1:02:53 PM ET
      $INCR
      Biotechnology: Pharmaceutical Preparations
      Health Care